Top Markets
#1 Islamic Coin Islamic Coin +151.52%
#2 Black Phoenix Black Phoenix +34.38%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +20.18%
#4 Akedo Akedo +12.99%
#5 Not in Employment, Education, or Training Not in Employment, Education, or Training +12.69%
#6 clBTC clBTC +11.91%
#7 OpenEden OpenEden +10.96%
#8 Fake World Assets Fake World Assets +9.99%
#9 HOME HOME +9.85%
#10 Pons Pons +9.50%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
Homology Medicines, Inc. Homology Medicines, Inc.

Homology Medicines, Inc.

FIXX
Rank in Stocks #39911
Homology Medicines, Inc. is a biotechnology firm dedicated to genetic... Homology Medicines, Inc. is a biotechnology firm dedicated to genetic therapeutics, striving to enhance the well-being of patients battling rare inherited disorders. The company leverages its unique platform, which employs adeno-associated virus vectors (AAVHSCs) originating from human hematopoietic stem cells, to introduce genetic treatments directly into the body. This approach facilitates either gene therapy or nuclease-free gene editing solutions for a range of genetic ailments. Crucially, Homology's diverse collection of AAVHSCs enables the precise targeting of multiple disease-affected tissues—such as the liver, central and peripheral nervous systems, bone marrow, heart, skeletal muscles, and eyes—all from a single administration. The leading candidate in their pipeline, HMI-102, is a gene therapy undergoing the Phase 2 pheNIX clinical trial, intended for adult patients with phenylketonuria (PKU). Beyond this, their development portfolio includes HMI-103 for pediatric PKU, HMI-202 targeting metachromatic leukodystrophy, HMI-203 for mucopolysaccharidosis type II, and HMI-104 designed to address paroxysmal nocturnal hemoglobinuria. Established in 2015, Homology Medicines, Inc. maintains its corporate headquarters in Bedford, Massachusetts.
Share Price
$0.9347
Last synced: 2024-03-25
Market Cap
$300.42K
Change (1 day)
0.75%
Change (1 year)
0.00%
Country
US
Trade Homology Medicines, Inc. (FIXX)

Category

Healthcare
P/E ratio for Homology Medicines, Inc. (FIXX)
P/E ratio as of 2026 TTM: 0
According to Homology Medicines, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Homology Medicines, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.